Bronchogen
$59.90
- Buy 5 and save 10%
- Buy 10 and save 15%
Legal Notice Regarding This Product
THIS PRODUCT IS STRICTLY INTENDED FOR RESEARCH USE ONLY. It is designated solely as a research chemical. Usage is confined to in vitro testing and laboratory experimentation exclusively. Information available on our website about this product is for educational purposes only and should not be interpreted as an endorsement or directive for use outside these bounds. Introducing this product into humans or animals by any route is strictly prohibited by law. Handling of this product should be undertaken only by licensed, qualified professionals.
This product is not to be used as a drug, food, or cosmetic. Misbranding, misusing, or mislabeling this product as a drug, food, or cosmetic is illegal. Users are responsible for complying with all applicable laws and regulations regarding the handling and use of this product.
The effect of Bronchogen, a tetrapeptide, was investigated on the bronchial epithelium and inflammatory activity in the lungs of rats with chronic obstructive pulmonary disease (COPD).
The results showed that bronchogen treatment normalized the cellular composition and profile of pro-inflammatory cytokines and enzymes in the bronchoalveolar space, resulting in decreased activity of neutrophilic inflammation in the lungs. Additionally, the structure of the bronchial epithelium, which was disturbed in the COPD model, was restored, accompanied by an increase in secretory immunoglobulin A and surfactant protein B, markers for local immunity and reducing alveolar surface tension, respectively.
Titova ON, Kuzubova NA, Lebedeva ES, Preobrazhenskaya TN, Surkova EA, Dvorakovskaya IV. [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY]. Ross Fiziol Zh Im I M Sechenova. 2017 Feb;103(2):201-8. Russian. PMID: 30199201.
